The CROCO (CROhn's Disease COhort Study) - study design and protocol
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00086164" target="_blank" >RIV/00023001:_____/25:00086164 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/25:10502932
Výsledek na webu
<a href="https://journals.sagepub.com/doi/epdf/10.1177/17562848251362594" target="_blank" >https://journals.sagepub.com/doi/epdf/10.1177/17562848251362594</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/17562848251362594" target="_blank" >10.1177/17562848251362594</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The CROCO (CROhn's Disease COhort Study) - study design and protocol
Popis výsledku v původním jazyce
Background: Crohn's disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease that can be associated with significant bowel damage and disability. The L & eacute;mann Index (LI) is a validated tool for measuring cumulative bowel damage in CD patients through a comprehensive assessment of stricturing, penetrating and surgical lesions. However, prospective studies evaluating bowel damage progression in recently diagnosed CD patients remain limited.Objectives: To characterise the absolute and longitudinal variations in bowel damage progression, as measured by the LI, in a cohort of recently diagnosed CD patients, and to assess its association with relevant disease features, including disease phenotype, treatment strategies, biomarkers and disability.Design: Study protocol for the Crohn's Disease Cohort Study (CROCO Study), a multicentre, European, prospective cohort study.Methods and analysis: Patients with recently diagnosed CD (within the previous 12 months) will be enrolled and followed up for 5 years. Patients will receive standard-of-care treatment determined by the practising gastroenterologist. Morphological assessments to measure the LI and to evaluate bowel damage progression will be performed at years 1, 3 and 5 after the diagnosis. Disability will be assessed annually using the Inflammatory Bowel Disease - Disability Index (IBD-DI). The primary outcome will be the absolute LI at year 3 following diagnosis. Predictors of bowel damage progression and the association between bowel damage and disability will be analysed.Discussion: The CROCO study represents a unique multicentre cohort of recently diagnosed CD patients, designed to advance the understanding of CD's natural history and evolution. It will facilitate the development of composite scores for predicting bowel damage progression and provide valuable tools for designing future disease-modification trials.Trial registration: NCT05420233.
Název v anglickém jazyce
The CROCO (CROhn's Disease COhort Study) - study design and protocol
Popis výsledku anglicky
Background: Crohn's disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease that can be associated with significant bowel damage and disability. The L & eacute;mann Index (LI) is a validated tool for measuring cumulative bowel damage in CD patients through a comprehensive assessment of stricturing, penetrating and surgical lesions. However, prospective studies evaluating bowel damage progression in recently diagnosed CD patients remain limited.Objectives: To characterise the absolute and longitudinal variations in bowel damage progression, as measured by the LI, in a cohort of recently diagnosed CD patients, and to assess its association with relevant disease features, including disease phenotype, treatment strategies, biomarkers and disability.Design: Study protocol for the Crohn's Disease Cohort Study (CROCO Study), a multicentre, European, prospective cohort study.Methods and analysis: Patients with recently diagnosed CD (within the previous 12 months) will be enrolled and followed up for 5 years. Patients will receive standard-of-care treatment determined by the practising gastroenterologist. Morphological assessments to measure the LI and to evaluate bowel damage progression will be performed at years 1, 3 and 5 after the diagnosis. Disability will be assessed annually using the Inflammatory Bowel Disease - Disability Index (IBD-DI). The primary outcome will be the absolute LI at year 3 following diagnosis. Predictors of bowel damage progression and the association between bowel damage and disability will be analysed.Discussion: The CROCO study represents a unique multicentre cohort of recently diagnosed CD patients, designed to advance the understanding of CD's natural history and evolution. It will facilitate the development of composite scores for predicting bowel damage progression and provide valuable tools for designing future disease-modification trials.Trial registration: NCT05420233.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30219 - Gastroenterology and hepatology
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Therapeutic advances in gastroenterology
ISSN
1756-283X
e-ISSN
1756-2848
Svazek periodika
18
Číslo periodika v rámci svazku
July 2025
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
"art. no. 17562848251362594"
Kód UT WoS článku
001563525900001
EID výsledku v databázi Scopus
2-s2.0-105024561007